Key Highlights

  • Loss per share was USD 0.10 against an estimate of a USD 0.134 loss.
  • Research and development expenses were USD 3.70 million, compared with USD 4.97 million.
  • Loss from operations was USD 5.66 million, compared with USD 6.73 million.
  • Cash and cash equivalents were USD 1.89 million at September 30, 2026.

TuHURA Biosciences (NASDAQ:HURA) reported a loss per share of USD 0.10 for the third quarter of 2026, compared with USD 0.14 in the prior-year quarter and against an estimate of a USD 0.134 loss. Weighted average shares outstanding were 64,998,838, compared with 50,666,430.

Loss from operations was USD 5.66 million, compared with USD 6.73 million. For the nine months ended September 30, 2026, loss per share was USD 0.37, compared with USD 0.50.

Operating Expenses

Research and development expenses were USD 3.70 million, compared with USD 4.97 million, and general and administrative expenses were USD 1.96 million, compared with USD 1.59 million. Total operating expenses were USD 5.66 million, compared with USD 6.73 million. The prior-year quarter included acquisition-related costs of USD 168 thousand.

Interest expense was USD 0.8 million, compared with less than USD 0.1 million, related primarily to the Parkview Credit Facility. Interest income was USD 3.7 thousand, compared with USD 6.1 thousand, and the prior-year quarter included grant income of USD 138 thousand.

Nine-Month Results

For the nine months, Research and Development expenses were USD 15.56 million, compared with USD 14.48 million, and general and administrative expenses were USD 6.40 million, compared with USD 5.47 million. Total operating expenses and loss from operations were USD 21.95 million, compared with USD 23.62 million.

Cash, Credit Facility and Clinical Program

Cash and cash equivalents were USD 1.89 million at September 30, 2026, compared with USD 3.62 million at the prior Balance Sheet date. The filing describes a USD 50 million revolving credit facility with Parkview Holdings One LLC.

The filing states that the company anticipates its existing Capital resources, including future cash proceeds from the Parkview Credit Facility, are sufficient to fund planned operations into 2028.

The filing states that in June 2025 the company initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0, administered as an adjunctive therapy to Keytruda, in first-line treatment for patients with advanced or metastatic Merkel cell carcinoma who are checkpoint inhibitor naive. The company anticipates topline results from the trial in the second half of 2027.

The filing states that in June 2025 the company acquired the rights to TBS-2025, a VISTA-inhibiting monoclonal antibody formerly known as KVA12123, through its Acquisition of Kineta, Inc. The company is planning a Phase 1b/2 trial of TBS-2025 in patients with relapsed or refractory mutNPM1 acute myeloid leukemia.

Under the Parkview Credit Facility, each borrowing may not exceed the greater of USD 1.7 million and the monthly budgeted expense amount in the company's expense budget for the immediately subsequent month.

The filing describes IFx-2.0, the company's lead product candidate, as an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors, and describes the Phase 3 trial as using the FDA's Accelerated Approval pathway.

TuHURA Biosciences Q3 2026 Earnings: Key Takeaways

TuHURA Biosciences reported a third quarter 2026 loss per share of USD 0.10 and a loss from operations of USD 5.66 million. Cash and cash equivalents were USD 1.89 million at September 30, 2026.